Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics.

Ponnayyan Sulochana SureshRavi Kumar JairamDevaraj V ChandrasekharAnera Balakrishna VinodRakesh A HiremathAnusha RajMohd ZainuddinRavi Kanth BhamidipatiRamesh Mullangi

Published in: European journal of drug metabolism and pharmacokinetics (2018)

The derived pharmacokinetic parameters (AUC and Cmax at 600 mg dose) and simulated plasma concentration-time profiles of ulixertinib in humans were predicted with good confidence by allometric approach.

Keyphrases

endothelial cells
signaling pathway
induced pluripotent stem cells
high fat diet induced
pluripotent stem cells
pi k akt
type diabetes
adipose tissue